Earnings Recovery For Nichi-Iko Unlikely Before Full Resumption Of Toyama Shipments
Japanese Generics Giant Still Suffering Following The Events Of 2021
Nichi-Iko still has a long road to recovery ahead as it attempts to get its Toyama plant back on its feet.
You may also be interested in...
Nichi-Iko Secures Up To ¥98.5bn Debt Relief As ADR Pushes Ahead
Troubled Japanese firm Nichi-Iko has currently has ¥55.8bn of debt forgiveness, which may expand to ¥98.5bn in the future. It currently faces regular payments until 2033 to settle all of its debts.
Nichi-Iko Set To Delist In March As Tamura Steps Down As CEO
After nearly two difficult years for Nichi-Iko Pharmaceutical, the firm has announced at it will be acquired by a private equity fund and delisted from the Toyko Stock Exchange in 2023 and its CEO will step down from his post.
Sawai Urges Japan To Take 'Best And Only Chance' To Reform Pricing Amid Generic Crisis
Kenzo Sawai, president of Japanese generics giant Sawai Pharmaceutical, talks about the firm’s strategy and backstory of efforts to maintain product supplies amid the country’s ongoing generic crisis in an exclusive interview. He also urges Japan to take "the best and only chance" to reform its drug pricing system to help the entire market survive.